PKO Investment Management Joint Stock Co Sells 500 Shares of Eli Lilly and Company $LLY

PKO Investment Management Joint Stock Co reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 3.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,926 shares of the company’s stock after selling 500 shares during the period. Eli Lilly and Company accounts for about 0.9% of PKO Investment Management Joint Stock Co’s investment portfolio, making the stock its 23rd largest holding. PKO Investment Management Joint Stock Co’s holdings in Eli Lilly and Company were worth $10,626,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of LLY. Occidental Asset Management LLC boosted its position in shares of Eli Lilly and Company by 0.7% in the 2nd quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock worth $1,533,000 after purchasing an additional 13 shares in the last quarter. New Insight Wealth Advisors boosted its holdings in Eli Lilly and Company by 3.4% in the second quarter. New Insight Wealth Advisors now owns 394 shares of the company’s stock worth $307,000 after acquiring an additional 13 shares in the last quarter. Dash Acquisitions Inc. boosted its holdings in Eli Lilly and Company by 2.8% in the second quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock worth $387,000 after acquiring an additional 13 shares in the last quarter. Nvest Financial LLC grew its stake in shares of Eli Lilly and Company by 0.6% in the second quarter. Nvest Financial LLC now owns 2,274 shares of the company’s stock worth $1,773,000 after acquiring an additional 13 shares during the last quarter. Finally, MPS Loria Financial Planners LLC increased its holdings in shares of Eli Lilly and Company by 1.9% during the second quarter. MPS Loria Financial Planners LLC now owns 699 shares of the company’s stock valued at $545,000 after acquiring an additional 13 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on LLY shares. Guggenheim reiterated a “buy” rating and issued a $1,163.00 price target on shares of Eli Lilly and Company in a research note on Wednesday, December 3rd. CICC Research upped their target price on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a research note on Thursday, November 13th. Loop Capital set a $950.00 price target on shares of Eli Lilly and Company in a research report on Monday, November 10th. Scotiabank began coverage on Eli Lilly and Company in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 price objective on the stock. Finally, UBS Group started coverage on Eli Lilly and Company in a report on Tuesday, January 6th. They issued a “buy” rating and a $1,250.00 target price for the company. Five investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Buy” and an average price target of $1,169.00.

Eli Lilly and Company Trading Down 0.5%

Shares of LLY stock opened at $1,075.90 on Wednesday. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The stock has a market capitalization of $1.02 trillion, a P/E ratio of 52.64, a P/E/G ratio of 0.78 and a beta of 0.35. The firm’s 50 day moving average is $1,044.24 and its 200 day moving average is $865.79.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 33.86%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s announced acquisition of Ventyx Biosciences offered a strategic complement to its weight?loss franchise by targeting inflammation (data showed benefit when combined with GLP?1 therapy); the deal helped calm investor concern after the Novo news and supported a rally. Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns
• Positive Sentiment: Lilly and NVIDIA will fund a $1B AI co?innovation lab over five years to speed drug discovery and manufacturing—this could lower R&D costs and shorten time?to?market for new drugs, a multi?year positive for pipeline value. Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab
• Positive Sentiment: Commercial demand traction: Humana’s CenterWell Pharmacy launching an employer program that uses Lilly’s GLP?1 drugs underscores ongoing demand and distribution pathways for Lilly’s marketed products. Humana’s CenterWell Pharmacy Launches Employer Venture Using Lilly’s GLP-1 Drugs
• Neutral Sentiment: Company guidance and seasonality: Analysts expect double?digit Q4 growth and Lilly has strong FY 2025/26 earnings expectations—these set a positive baseline but already appear priced into the stock. What to Expect From Eli Lilly’s Q4 2025 Earnings Report
• Neutral Sentiment: Lilly says it is confident about supply readiness for its oral weight?loss candidate ahead of an anticipated U.S. approval—reduces one operational risk but doesn’t remove competitive or regulatory uncertainty. Lilly says it’s confident in weight-loss pill supply ahead of U.S. approval
• Negative Sentiment: Competitive pressure: Novo Nordisk’s immediate nationwide rollout of the Wegovy oral pill surprised some investors and triggered a pullback in LLY shares as markets priced higher competition in the oral GLP?1 market. Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.